Krystal Biotech, Inc. (NASDAQ: KRYS) Stock Competitors & Peer Comparison

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, VRTX has a market cap of 131.9B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while VRTX trades at $514.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas VRTX's P/E ratio is 27.31. In terms of profitability, KRYS's ROE is +0.19%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, KRYS is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check VRTX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, REGN has a market cap of 81.8B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while REGN trades at $776.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas REGN's P/E ratio is 17.40. In terms of profitability, KRYS's ROE is +0.19%, compared to REGN's ROE of +0.14%. Regarding short-term risk, KRYS is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check REGN's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas VRNA's P/E ratio is -102.80. In terms of profitability, KRYS's ROE is +0.19%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, KRYS is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check VRNA's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, ARGX has a market cap of 61.6B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while ARGX trades at $983.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas ARGX's P/E ratio is 89.40. In terms of profitability, KRYS's ROE is +0.19%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, KRYS is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check ARGX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, MRNA has a market cap of 58.2B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while MRNA trades at $142.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas MRNA's P/E ratio is -18.00. In terms of profitability, KRYS's ROE is +0.19%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, KRYS is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check MRNA's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, RVMDW has a market cap of 44.5B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while RVMDW trades at $11.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas RVMDW's P/E ratio is -1.29. In terms of profitability, KRYS's ROE is +0.19%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, KRYS is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check RVMDW's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, RVMD has a market cap of 43.6B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while RVMD trades at $203.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas RVMD's P/E ratio is -23.26. In terms of profitability, KRYS's ROE is +0.19%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, KRYS is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check RVMD's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas SGEN's P/E ratio is -57.19. In terms of profitability, KRYS's ROE is +0.19%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, KRYS is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check SGEN's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, ONC has a market cap of 37.8B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while ONC trades at $348.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas ONC's P/E ratio is 62.29. In terms of profitability, KRYS's ROE is +0.19%, compared to ONC's ROE of +0.14%. Regarding short-term risk, KRYS is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check ONC's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, ALNY has a market cap of 33.5B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while ALNY trades at $241.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas ALNY's P/E ratio is 45.04. In terms of profitability, KRYS's ROE is +0.19%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, KRYS is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ALNY's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, ROIV has a market cap of 29.6B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while ROIV trades at $39.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas ROIV's P/E ratio is -39.02. In terms of profitability, KRYS's ROE is +0.19%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, KRYS is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ROIV's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, INSM has a market cap of 27.2B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while INSM trades at $119.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas INSM's P/E ratio is -30.49. In terms of profitability, KRYS's ROE is +0.19%, compared to INSM's ROE of -1.11%. Regarding short-term risk, KRYS is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check INSM's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, BNTX has a market cap of 24.8B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while BNTX trades at $97.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas BNTX's P/E ratio is -12.82. In terms of profitability, KRYS's ROE is +0.19%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, KRYS is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check BNTX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, INCY has a market cap of 24.8B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while INCY trades at $121.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas INCY's P/E ratio is 16.42. In terms of profitability, KRYS's ROE is +0.19%, compared to INCY's ROE of +0.30%. Regarding short-term risk, KRYS is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check INCY's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, UTHR has a market cap of 21.3B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while UTHR trades at $501.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas UTHR's P/E ratio is 17.99. In terms of profitability, KRYS's ROE is +0.19%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, KRYS is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check UTHR's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas BGNE's P/E ratio is -22.55. In terms of profitability, KRYS's ROE is +0.19%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, KRYS is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check BGNE's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, GMAB has a market cap of 20B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while GMAB trades at $34.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas GMAB's P/E ratio is 24.60. In terms of profitability, KRYS's ROE is +0.19%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, KRYS is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check GMAB's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, KRYS's ROE is +0.19%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, KRYS is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check DNA-WT's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, ASND has a market cap of 16.5B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while ASND trades at $235.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas ASND's P/E ratio is -109.47. In terms of profitability, KRYS's ROE is +0.19%, compared to ASND's ROE of +1.90%. Regarding short-term risk, KRYS is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ASND's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, NBIX has a market cap of 15.8B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while NBIX trades at $149.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas NBIX's P/E ratio is 22.72. In terms of profitability, KRYS's ROE is +0.19%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, KRYS is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check NBIX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, JAZZ has a market cap of 15.4B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while JAZZ trades at $240.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas JAZZ's P/E ratio is 9.17. In terms of profitability, KRYS's ROE is +0.19%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, KRYS is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check JAZZ's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, SMMT has a market cap of 14.7B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while SMMT trades at $17.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas SMMT's P/E ratio is -16.45. In terms of profitability, KRYS's ROE is +0.19%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, KRYS is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check SMMT's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, BBIO has a market cap of 14.2B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while BBIO trades at $68.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas BBIO's P/E ratio is -19.35. In terms of profitability, KRYS's ROE is +0.19%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, KRYS is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check BBIO's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while EXEL trades at $56.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas EXEL's P/E ratio is 16.06. In terms of profitability, KRYS's ROE is +0.19%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, KRYS is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check EXEL's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, BMRN has a market cap of 12.8B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while BMRN trades at $64.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas BMRN's P/E ratio is 31.93. In terms of profitability, KRYS's ROE is +0.19%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, KRYS is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check BMRN's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, HALO has a market cap of 12.8B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while HALO trades at $106.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas HALO's P/E ratio is 20.14. In terms of profitability, KRYS's ROE is +0.19%, compared to HALO's ROE of +1.81%. Regarding short-term risk, KRYS is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check HALO's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas KRTX's P/E ratio is -28.09. In terms of profitability, KRYS's ROE is +0.19%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, KRYS is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check KRTX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, MDGL has a market cap of 12.5B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while MDGL trades at $518.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas MDGL's P/E ratio is -42.19. In terms of profitability, KRYS's ROE is +0.19%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, KRYS is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check MDGL's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, ARWR has a market cap of 11.4B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while ARWR trades at $72.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas ARWR's P/E ratio is -35.85. In terms of profitability, KRYS's ROE is +0.19%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, KRYS is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ARWR's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while TECH trades at $72.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas TECH's P/E ratio is 37.25. In terms of profitability, KRYS's ROE is +0.19%, compared to TECH's ROE of +0.09%. Regarding short-term risk, KRYS is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check TECH's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas RNAM's P/E ratio is -17.39. In terms of profitability, KRYS's ROE is +0.19%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, KRYS is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check RNAM's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, AXSM has a market cap of 11.1B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while AXSM trades at $208.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas AXSM's P/E ratio is -56.55. In terms of profitability, KRYS's ROE is +0.19%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, KRYS is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check AXSM's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas RXDX's P/E ratio is -56.47. In terms of profitability, KRYS's ROE is +0.19%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, KRYS is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check RXDX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, PTGX has a market cap of 9.5B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while PTGX trades at $143.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas PTGX's P/E ratio is 143.48. In terms of profitability, KRYS's ROE is +0.19%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, KRYS is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check PTGX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, KYMR has a market cap of 9.4B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while KYMR trades at $113.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas KYMR's P/E ratio is -35.82. In terms of profitability, KRYS's ROE is +0.19%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, KRYS is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check KYMR's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, PRAX has a market cap of 9.2B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while PRAX trades at $315.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas PRAX's P/E ratio is -25.58. In terms of profitability, KRYS's ROE is +0.19%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, KRYS is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check PRAX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas NUVL's P/E ratio is -21.79. In terms of profitability, KRYS's ROE is +0.19%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, KRYS is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check NUVL's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, CYTK has a market cap of 9B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while CYTK trades at $69.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas CYTK's P/E ratio is -10.03. In terms of profitability, KRYS's ROE is +0.19%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, KRYS is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check CYTK's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas CRNX's P/E ratio is -16.86. In terms of profitability, KRYS's ROE is +0.19%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, KRYS is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check CRNX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, TXG has a market cap of 8.9B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while TXG trades at $74.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas TXG's P/E ratio is -118.83. In terms of profitability, KRYS's ROE is +0.19%, compared to TXG's ROE of -0.09%. Regarding short-term risk, KRYS is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check TXG's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, IBRX has a market cap of 8.8B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while IBRX trades at $7.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas IBRX's P/E ratio is -8.63. In terms of profitability, KRYS's ROE is +0.19%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, KRYS is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check IBRX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas IMGN's P/E ratio is -111.55. In terms of profitability, KRYS's ROE is +0.19%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, KRYS is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check IMGN's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while PCVX trades at $58.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas PCVX's P/E ratio is -7.80. In terms of profitability, KRYS's ROE is +0.19%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, KRYS is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check PCVX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, IONS has a market cap of 8.5B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while IONS trades at $47.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas IONS's P/E ratio is -29.91. In terms of profitability, KRYS's ROE is +0.19%, compared to IONS's ROE of -1.11%. Regarding short-term risk, KRYS is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check IONS's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, TWST has a market cap of 8.4B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while TWST trades at $136.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas TWST's P/E ratio is -60.70. In terms of profitability, KRYS's ROE is +0.19%, compared to TWST's ROE of -0.30%. Regarding short-term risk, KRYS is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check TWST's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas BPMC's P/E ratio is -51.58. In terms of profitability, KRYS's ROE is +0.19%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, KRYS is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check BPMC's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas APGE's P/E ratio is -31.19. In terms of profitability, KRYS's ROE is +0.19%, compared to APGE's ROE of -0.30%. Regarding short-term risk, KRYS is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check APGE's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, ABVX has a market cap of 8.3B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while ABVX trades at $107.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas ABVX's P/E ratio is -59.54. In terms of profitability, KRYS's ROE is +0.19%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, KRYS is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ABVX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while TGTX trades at $53.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas TGTX's P/E ratio is 19.57. In terms of profitability, KRYS's ROE is +0.19%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, KRYS is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check TGTX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas CERE's P/E ratio is -16.47. In terms of profitability, KRYS's ROE is +0.19%, compared to CERE's ROE of -0.72%. Regarding short-term risk, KRYS is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check CERE's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, SYRE has a market cap of 7.9B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while SYRE trades at $89.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas SYRE's P/E ratio is -46.56. In terms of profitability, KRYS's ROE is +0.19%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, KRYS is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check SYRE's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, IMVT has a market cap of 7.8B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while IMVT trades at $36.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas IMVT's P/E ratio is -13.35. In terms of profitability, KRYS's ROE is +0.19%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, KRYS is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check IMVT's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas MTSR's P/E ratio is -23.58. In terms of profitability, KRYS's ROE is +0.19%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, KRYS is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check MTSR's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, CAI has a market cap of 7.4B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while CAI trades at $28.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas CAI's P/E ratio is 73.19. In terms of profitability, KRYS's ROE is +0.19%, compared to CAI's ROE of +0.19%. Regarding short-term risk, KRYS is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check CAI's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while RYTM trades at $97.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas RYTM's P/E ratio is -32.94. In terms of profitability, KRYS's ROE is +0.19%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, KRYS is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check RYTM's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, BLTE has a market cap of 6.9B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while BLTE trades at $169.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas BLTE's P/E ratio is -92.51. In terms of profitability, KRYS's ROE is +0.19%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, KRYS is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check BLTE's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas MRUS's P/E ratio is -17.05. In terms of profitability, KRYS's ROE is +0.19%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, KRYS is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check MRUS's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas ACLX's P/E ratio is -28.27. In terms of profitability, KRYS's ROE is +0.19%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, KRYS is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check ACLX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas RETA's P/E ratio is -66.29. In terms of profitability, KRYS's ROE is +0.19%, compared to RETA's ROE of +0.47%. Regarding short-term risk, KRYS is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check RETA's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, CGON has a market cap of 6.5B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while CGON trades at $73.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas CGON's P/E ratio is -27.43. In terms of profitability, KRYS's ROE is +0.19%, compared to CGON's ROE of -0.25%. Regarding short-term risk, KRYS is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check CGON's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas CNTA's P/E ratio is -22.63. In terms of profitability, KRYS's ROE is +0.19%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, KRYS is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check CNTA's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, SRRK has a market cap of 6.2B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while SRRK trades at $48.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas SRRK's P/E ratio is -15.03. In terms of profitability, KRYS's ROE is +0.19%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, KRYS is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check SRRK's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while TVTX trades at $61.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas TVTX's P/E ratio is -146.20. In terms of profitability, KRYS's ROE is +0.19%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, KRYS is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check TVTX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, DNTH has a market cap of 6B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while DNTH trades at $104.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas DNTH's P/E ratio is -25.95. In terms of profitability, KRYS's ROE is +0.19%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, KRYS is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check DNTH's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while MIRM trades at $93.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas MIRM's P/E ratio is -6.65. In terms of profitability, KRYS's ROE is +0.19%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, KRYS is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check MIRM's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, ORKA has a market cap of 5.8B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while ORKA trades at $90.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas ORKA's P/E ratio is -49.48. In terms of profitability, KRYS's ROE is +0.19%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, KRYS is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ORKA's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while COGT trades at $32.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas COGT's P/E ratio is -15.83. In terms of profitability, KRYS's ROE is +0.19%, compared to COGT's ROE of -0.73%. Regarding short-term risk, KRYS is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check COGT's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, XENE has a market cap of 5.6B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while XENE trades at $56.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas XENE's P/E ratio is -12.38. In terms of profitability, KRYS's ROE is +0.19%, compared to XENE's ROE of -0.44%. Regarding short-term risk, KRYS is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check XENE's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, LGND has a market cap of 5.6B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while LGND trades at $271.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas LGND's P/E ratio is 30.81. In terms of profitability, KRYS's ROE is +0.19%, compared to LGND's ROE of +0.20%. Regarding short-term risk, KRYS is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check LGND's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas CDTX's P/E ratio is -19.77. In terms of profitability, KRYS's ROE is +0.19%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, KRYS is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check CDTX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, ERAS has a market cap of 5.6B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while ERAS trades at $15.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas ERAS's P/E ratio is -17.38. In terms of profitability, KRYS's ROE is +0.19%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, KRYS is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ERAS's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while PTCT trades at $65.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas PTCT's P/E ratio is -28.53. In terms of profitability, KRYS's ROE is +0.19%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, KRYS is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check PTCT's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, KRYS's ROE is +0.19%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, KRYS is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check ABCM's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas ISEE's P/E ratio is -22.44. In terms of profitability, KRYS's ROE is +0.19%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, KRYS is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check ISEE's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, DFTX has a market cap of 5.3B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while DFTX trades at $36.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas DFTX's P/E ratio is N/A. In terms of profitability, KRYS's ROE is +0.19%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, KRYS is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check DFTX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas APLS's P/E ratio is 38.35. In terms of profitability, KRYS's ROE is +0.19%, compared to APLS's ROE of +0.40%. Regarding short-term risk, KRYS is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check APLS's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while CRSP trades at $51.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas CRSP's P/E ratio is -11.13. In terms of profitability, KRYS's ROE is +0.19%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, KRYS is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check CRSP's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while EWTX trades at $43.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas EWTX's P/E ratio is -24.12. In terms of profitability, KRYS's ROE is +0.19%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, KRYS is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check EWTX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas TERN's P/E ratio is -51.41. In terms of profitability, KRYS's ROE is +0.19%, compared to TERN's ROE of -0.20%. Regarding short-term risk, KRYS is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check TERN's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, ACAD has a market cap of 4.7B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while ACAD trades at $26.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas ACAD's P/E ratio is 12.40. In terms of profitability, KRYS's ROE is +0.19%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, KRYS is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ACAD's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas FOLD's P/E ratio is -161.00. In terms of profitability, KRYS's ROE is +0.19%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, KRYS is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check FOLD's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas AKRO's P/E ratio is -14.57. In terms of profitability, KRYS's ROE is +0.19%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, KRYS is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check AKRO's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas ALPN's P/E ratio is -101.52. In terms of profitability, KRYS's ROE is +0.19%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, KRYS is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check ALPN's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while MANE trades at $102.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas MANE's P/E ratio is -32.36. In terms of profitability, KRYS's ROE is +0.19%, compared to MANE's ROE of -0.38%. Regarding short-term risk, KRYS is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check MANE's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas OPT's P/E ratio is -1.52. In terms of profitability, KRYS's ROE is +0.19%, compared to OPT's ROE of +1.18%. Regarding short-term risk, KRYS is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check OPT's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas PRTC's P/E ratio is -3.78. In terms of profitability, KRYS's ROE is +0.19%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, KRYS is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check PRTC's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, PBLS has a market cap of 4.2B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while PBLS trades at $35.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas PBLS's P/E ratio is -41.09. In terms of profitability, KRYS's ROE is +0.19%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, KRYS is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check PBLS's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, RLAY has a market cap of 4.2B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while RLAY trades at $18.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas RLAY's P/E ratio is -12.14. In terms of profitability, KRYS's ROE is +0.19%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, KRYS is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check RLAY's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, IOVA has a market cap of 4.1B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while IOVA trades at $9.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas IOVA's P/E ratio is -12.68. In terms of profitability, KRYS's ROE is +0.19%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, KRYS is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check IOVA's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas MRTX's P/E ratio is -4.82. In terms of profitability, KRYS's ROE is +0.19%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, KRYS is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check MRTX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, CELC has a market cap of 4.1B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while CELC trades at $81.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas CELC's P/E ratio is -19.43. In terms of profitability, KRYS's ROE is +0.19%, compared to CELC's ROE of -3.51%. Regarding short-term risk, KRYS is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check CELC's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, TNGX has a market cap of 4B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while TNGX trades at $23.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas TNGX's P/E ratio is -29.57. In terms of profitability, KRYS's ROE is +0.19%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, KRYS is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check TNGX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while TLX trades at $12.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas TLX's P/E ratio is 122.96. In terms of profitability, KRYS's ROE is +0.19%, compared to TLX's ROE of +0.07%. Regarding short-term risk, KRYS is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check TLX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, ADPT has a market cap of 4B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while ADPT trades at $26.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas ADPT's P/E ratio is -60.44. In terms of profitability, KRYS's ROE is +0.19%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, KRYS is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ADPT's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while ELVN trades at $53.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas ELVN's P/E ratio is -32.59. In terms of profitability, KRYS's ROE is +0.19%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, KRYS is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ELVN's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas CPRX's P/E ratio is 12.30. In terms of profitability, KRYS's ROE is +0.19%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, KRYS is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check CPRX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas RYZB's P/E ratio is -57.86. In terms of profitability, KRYS's ROE is +0.19%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, KRYS is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check RYZB's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, AMLX has a market cap of 3.7B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while AMLX trades at $33.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas AMLX's P/E ratio is -22.43. In terms of profitability, KRYS's ROE is +0.19%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, KRYS is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check AMLX's competition here

Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KRYS stands at 10B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, KRYS is priced at $335.99 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KRYS currently has a P/E ratio of 42.61, whereas CBAY's P/E ratio is -32.81. In terms of profitability, KRYS's ROE is +0.19%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, KRYS is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check CBAY's competition here